1. Crescent Biopharma granted 129,626 shares to attract new employees. 2. Options have a 10-year term, exercised at $13.21 per share. 3. Company focuses on advancing cancer therapies with innovative drug pipeline. 4. Vesting begins after one year, incentivizing employee retention. 5. Crescent aims to become a leading oncology company.
FAQ
Why Bullish?
The option grants signal confidence in future projects, potentially driving interest. Historical examples like similar grants often lead to positive market reactions.
How important is it?
The information reflects strategic decisions likely to affect CBIO's future growth and investment appeal.
Why Short Term?
Immediate employee retention and market optimism can lead to short-term price gains. Long-term impact depends on successful drug pipeline developments.
Crescent Biopharma (CBIO) Grants Equity Inducement Awards to Non-Executive Employees
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO) has announced the approval of equity inducement awards for three non-executive employees. This approval comes from the independent directors on the Company’s Board, marking a significant commitment to equity compensation as part of their hiring strategy. The awards are designed to enhance recruitment and retention efforts in the fast-evolving biotechnology sector.
Details of the Inducement Awards
The Board of Directors approved the grant of options to purchase a total of 129,626 shares of Crescent’s ordinary shares under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). These options were approved on December 13, 2025, and formally granted on December 15, 2025.
- Options Granted: 129,626 shares
- Exercise Price: $13.21, the closing price on December 15, 2025
- Vesting Schedule:
- One-fourth (1/4th) vesting on the first anniversary of employment
- One-forty-eighth (1/48th) vesting monthly thereafter
- Term: 10 years
The options granted are subject to the terms of the Inducement Plan and relevant option agreements.
Implications for Crescent Biopharma (CBIO)
This move aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's focus on quality recruitment practices. The options granted were deemed crucial for the employees’ acceptance of their roles at Crescent, reinforcing the Company’s commitment to cultivating a strong workforce.
Crescent Biopharma aims to build a leading oncology platform by developing cutting-edge therapies for cancer patients. The Company’s strategic focus includes a pipeline with advanced programs, such as its PD-1 x VEGF bispecific antibody and innovative antibody-drug conjugates (ADCs).
About Crescent Biopharma
Crescent Biopharma envisions transforming cancer treatment through the development of potentially groundbreaking therapies. By leveraging various treatment modalities and established targets, the Company plans to accelerate the introduction of both single-agent and combination therapies targeting a range of solid tumors.
For further details, visit www.crescentbiopharma.com and follow Crescent Biopharma on LinkedIn and X.
Contact Information
For media inquiries, please contact:
Amy Reilly
Chief Communications Officer
Email: amy.reilly@crescentbiopharma.com
Phone: 617-465-0586